Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Kroon, Féline P B ^a   van der Burg, Lennart R A ^a   Ramiro, Sofia ^b   Landewé, Robert B M ^b,c   Buchbinder, Rachelle ^d   Falzon, Louise ^e   van der Heijde, Désirée ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d MONASH UNIVERSITY   (Australia)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; C REACTIVE PROTEIN; CELECOXIB; DICLOFENAC; DIFLUNISAL; ETORICOXIB; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIRAZOLAC; PIROXICAM; PLACEBO; SULINDAC; TENOXICAM; XIMOPROFEN; CYCLOOXYGENASE 2 INHIBITOR;

ANKYLOSING SPONDYLITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUROLOGIC DISEASE; NUMERIC RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SHORT FORM 36; SKIN DISEASE; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; ADULT; COHORT ANALYSIS; META ANALYSIS; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONDYLITIS, ANKYLOSING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INDOMETHACIN; NAPROXEN; PAIN; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING;

EID: 84957411731     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010952.pub2     Document Type: Review

References (186)

1. Ansell BM. A comparative study of Butacote and naproxen in ankylosing spondylitis. Journal of International Medical Research 1977;5(Suppl 2):95.
2. Ansell BM, Major G, Liyanage SP, Gumpel JM, Seifert MH, Mathews JA, et al. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. Annals of the Rheumatic Diseases 1978;37(5):436-9.
3. Astorga G. Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis. European Journal of Rheumatology and Inflammation 1987;9(2):70-3.
4. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. Journal of Rheumatology 2006;33(9):1805-12.
5. Batlle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. Journal of Rheumatology 1996;23(7):1200-6.
6. Boersma JW. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scandinavian Journal of Rheumatology 1976;5(1):60-4.
7. Caldwell JR, Altman RD, Burch FX, Calin A. Treatment of ankylosing spondylitis with oxaprozin: A comparison with indomethacin. Seminars in Arthritis and Rheumatism 1986;15(3 Suppl 2):95-100.
8. Calin A, Britton M. Sulindac in ankylosing spondylitis. Double-blind evaluation of sulindac and indomethacin. JAMA 1979;242(17):1885-6.
9. Carcassi C, La Nasa G, Perpignano G. A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis. Drugs Under Experimental and Clinical Research 1990;16(1):29-37.
10. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri-Guegnault B, et al. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scandinavian Journal of Rheumatology 1994;23(5):243-8.
11. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 1999;38(3):235-44.
12. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis and Rheumatism 2001;44(1):180-5.
13. Ebner W, Poal Ballarin JM, Boussina I. Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. Arzneimittel-Forschung 1983;33(4A):660-3.
14. Franssen MJ, Gribnau FW, van de Putte LB. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clinical Rheumatology 1986;5(2):210-20.
15. Good A, Mena H. Treatment of ankylosing spondylitis with flurbiprofen and indomethacin. Current Medical Research and Opinion 1977;5(1):117-21.
16. Mena HR, Good AE. Management of ankylosing spondylitis with flurbiprofen or indomethacin. Southern Medical Journal 1977;70(8):945-7.
17. Heinrichs K, Kriech W. Treatment of spondylitis ankylosans: Controlled comparative study with tiaprofenic acid and diclofenac [Behandlung der Spondylitis Ankylosans: Kontrollierte Vergleichsstudie mit Tiaprofensaure und Diclofenac]. Medizinische Klinik 1985;80(21):597-601.
18. Jessop JD. Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatology and Rehabilitation 1976;Suppl:37-42.
19. Calabro JJ. Efficacy of diclofenac in ankylosing spondylitis. American Journal of Medicine 1986;80(4B):58-63.
20. Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. Journal of Rheumatology 1987;14(1):118-23.
21. Khan MA. Diclofenac in the treatment of ankylosing spondylitis: review of worldwide clinical experience and report of a double-blind comparison with indomethacin. Seminars in Arthritis and Rheumatism 1985;15(2 Suppl 1):80-4.
22. Lehtinen K, Kaarela K, Mäkisara P, Holttinen K, Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. British Journal of Rheumatology 1984;23(1):52-6.
23. Lomen PL, Turner LF, Lamborn KR, Brinn EL. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin. American Journal of Medicine 1986;80(3A):127-32.
24. Lomen PL, Turner LF, Lamborn KR, Brinn EL, Sattler LP. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. American Journal of Medicine 1986;80(3A):120-6.
25. Mena HR, Willkens RF. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. European Journal of Clinical Pharmacology 1977;11(4):263-6.
26. Muller-Fassbender H. Ketoprofen in ankylosing spondylitis [Ketoprofen bei Morbus Bechterew]. Therapiewoche 1985;35(21):2619-24.
27. Myklebust G. Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew's syndrome. A double-blind parallel multicenter study [Naproxen sammenlignet med piroxicam ved reumatoid artritt og Bechterews syndrom]. Tidsskrift for Den Norske Lægeforening 1986;106(17-8):1485-7.
28. Nahir AM, Scharf Y. A comparative study of diclofenac and sulindac in ankylosing spondylitis. Rheumatology and Rehabilitation 1980;19(3):189-98.
29. Nissilä M, Kajander A. Proquazone (Biarison) and indomethacin (Indocid) in the treatment of ankylosing spondylitis. Two comparative, clinical, double-blind studies. Scandinavian Journal of Rheumatology. Supplement 1978;21:36-9.
30. Nissilä M, Kajander A. Proquazone (Biarison) and indomethacin (Indocid) in the treatment of ankylosing spondylitis. Two comparative, clinical, double-blind studies. Scandinavian Journal of Rheumatology. Supplement 1978;21:36-9.
31. Palferman TG, Webley M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. European Journal of Rheumatology and Inflammation 1991;11(2):23-9.
32. Pasero G, Ruju G, Marcolongo R, Senesi M, Seni U, Mannoni A, et al. Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study. Current Therapeutic Research - Clinical and Experimental 1994;55(7):833-42.
33. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. NSAIDs retard radiographic spinal progression over two years in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis. Zeitschrift fur Rheumatologie 2011;70:102-3.
34. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases 2012;71(10):1616-22.
35. Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. Scandinavian Journal of Rheumatology. Supplement 1980;36:1-7.
36. Santo JE, Queiroz MV. Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis. Journal of International Medical Research 1988;16(2):150-6.
37. Schwarzer AC, Cohen M, Arnold MH, Kelly D, McNaught P, Brooks PM. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Current Medical Research and Opinion 1990;11(10):648-53.
38. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Annals of the Rheumatic Diseases 2008;67(3):323-9.
39. Simpson MR, Simpson NR, Scott BO, Beatty DC. A controlled study of flufenamic acid in ankylosing spondylitis. A preliminary report. Annals of Physical Medicine 1966;Suppl:126-8.
40. Sydnes OA. Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial. British Journal of Clinical Practice 1981;35(1):40-4.
41. Tannenbaum H, DeCoteau WE, Esdaile JM. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Current Therapeutic Research - Clinical and Experimental 1984;36(3):426-35.
42. Gossec L, van der Heijde D, Meilian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Annals of the Rheumatic Diseases 2005;64(11):1563-7.
43. van der Heijde D, Baraf HSB, Ramos-Remus C, Calin A, Weaver AL, SchiffM, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis and Rheumatism 2005;52(4):1205-15.
44. Villa Alcázar LF, de Buergo M, Rico Lenza H, Montull Fruitós E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Journal of Rheumatology 1996;23(7):1194-9.
45. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2012;71(10):1623-9.
46. Wanders A, van der Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis and Rheumatism 2005;52(6):1756-65.
47. Amstrong RD, Laurent R, Panayi GS. A comparison of indoprofen and indomethacin in the treatment of ankylosing spondylitis. Pharmatherapeutica 1984;3(10):637-41.
48. Bird HA, Rhind VM, Pickup ME, Wright V. A comparative study of benoxaprofen and indomethacin in ankylosing spondylitis. Journal of Rheumatology. Supplement 1980;6:139-42.
49. Burry HC, Siebers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. New Zealand Medical Journal 1980;92(670):309-11.
50. Byron MA, Steele CE. A double-blind crossover study comparing tolmetin sodium and naproxen in the treatment of ankylosing spondylitis. Current Medical Research and Opinion 1982;7:670-6.
51. Calin A, Grahame R. Double-bind cross-over trial of flurbiprofen and phenylbutazone in ankylosing spondylitis. British Medical Journal 1974;4(5943):496-9.
52. Charlot J, Villiaumey J. A comparative study of benoxaprofen and ketoprofen in ankylosing spondylitis. European Journal of Rheumatology and Inflammation 1982;5(2):277-81.
53. Dougados M, Caporal R, Doury P, Thiesce A, Pattin S, Laffez B, et al. A double blind crossover placebo controlled trial of ximoprofen in as. Journal of Rheumatology 1989;16(8):1167-9.
54. Doury P, Roux H. Isoxicam vs ketoprofen in ankylosing spondylitis. British Journal of Clinical Pharmacology 1986;22(Suppl 2):157S-60S.
55. Esdaile J, Rothwell R, MacLaughlin K, Percy J, Hawkins D. Double-blind comparison of tolmetin sodium and indomethacin in ankylosing spondylitis. Journal of Rheumatology 1982;9(1):69-74.
56. Gibson T, Laurent R. Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study. Rheumatology and Rehabilitation 1980;19(3):189-92.
57. Harkness AJ, Burry HC, Grahame R. A trial of feprazone in ankylosing spondylitis. Rheumatology and Rehabilitation 1977;16(3):158-61.
58. Johnsen V, Brun JG, Fjeld E, Hansen K, Sydnes OA, Ugstad MB. Morning stiffness and nightime pain in ankylosing spondylitis. A comparison between enteric-coated and plain naproxen tablets. European Journal of Rheumatology & Inflammation 1992;12(2):37-42.
59. Kennedy AC, Germain BF, Goldman AL, Vreede PD. A double-blind, crossover comparison of ketoprofen and indomethacin in ankylosing spondylitis. Advances in Therapy 1991;8(3):148-56.
60. Kinsella TD, MacKenzie KR, Kim SO, Johnson LG. Evaluation of indomethacin by a controlled, cross-over technique in 30 patients with ankylosing spondylitis. Canadian Medical Association Journal 1967;96(22):1454-9.
61. Mayrhofer F, Broll H, Eberl R, Ebner W, Klein G, Rainer F, et al. Tenoxicam versus diclofenac in patients with ankylosing spondylitis. A double-blind study. Drug Investigation 1990;2(Suppl 3):52-3.
62. Peloso PM, Gammaitoni A, Smugar SS, Wang H, Moore AR. Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskeletal Disorders 2011;12:165.
63. Peter E. A double blind comparison of naproxen and indomethacin on the after-midnight-pain of patients with morbus bechterew [Wirkungsvergleich von Naproxen und Indometacin im Doppelblindversuch beim Nachmitternachtsschmerz von Morbus Bechterew]. Arzneimittel-Forschung 1975;25(2A):324-5.
64. Sadowska-Wroblewska M, Garwolinska H, Filipovicz-Sosnowska A. Azapropazone versus indomethacin in a double blind test with patients with ankylosing spondylitis [Azapropazon Versus Indometacin im Doppelblindversuch bei Patienten mit Spondylitis ankylosans]. Zeitschrift für Rheumatologie 1980;39(11-2):406-11.
65. Schattenkirchner M, Müller-Fassbender H, Melzer H. An open long-term study of piroxicam in ankylosing spondylitis patients [Eine offene Langzeitstudie mit Piroxicam bei Patienten mit Spondylitis ankylosans (M. Marie-Strümpell, M. Bechterew)]. Aktuelle Rheumatologie 1980;5:38-42.
66. Shipley M, Berry H, Bloom B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment. Rheumatology and Rehabilitation 1980;19(2):122-5.
67. Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Annals of the Rheumatic Diseases 2014;73(1):108-13.
68. Simpson MR, Simpson NR, Masheter HC. A controlled study of flufenamic acid in ankylosing spondylitis. A final report and follow-up study. Annals of Physical Medicine 1968;9(6):229-33.
69. Sturrock RD, Hart FD. Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Annals of the Rheumatic Diseases 1974;33(2):129-31.
70. Thompson M, Akyol MS. A controlled comparative trial of Butacote and fenclofenac in the treatment of ankylosing spondylitis. Journal of International Medical Research 1977;5(Suppl 2):96-9.
71. Van Gerwen F, Van der Korst JK, Gribnau FW. Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Annals of the Rheumatic Diseases 1978;37(1):85-8.
72. Wasner C, Britton MC, Kraines RG, Kaye RL, Bobrove AM, Fries JF. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. JAMA 1981;246(19):2168-72.
73. Wordsworth BP, Ebringer RW, Coggins E, Smith S. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatology and Rehabilitation 1980;19(4):260-3.
74. Unknown. A nonsteroidal anti-inflammatory agent. Indomethacin (indocin). JAMA 1966;196(7):651-2.
75. Acqaviva B, Cayla J, Delcambre B, Le GoffP, Loyau G, Serratrice G, et al. Clinical study of Bi-Profenid in rheumatologic practice [French]. La Semaine des Hôpitaux 1983;59(46):3229-34.
76. Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis [German]. Arzneimittel-Forschung 1975;25(2A):315-8.
77. Bachmann F. Comparison between sustained release formulations of ibuprofen and indomethacin in treatment of ankylosing spondylitis [Zur Medikamentösen Therapie der Ankylosierenden Spondylitis mit Ibuprofen (Dolgit Retard) im Vergleich zu Indometacin Retard]. Therapiewoche 1984;34:4958-64.
78. Baerwald CH, Willeke A, Lies S, Goebel KM, Engel HJ. Efficacy and tolerance of oral hydrolytic enzymes in ankylosing spondylitis as compared with indomethacin: A controlled double-blind prospective clinical trial. Journal of Clinical Research 1999;2:17-34.
79. Becvar R, Pavelka K Jr. Ethophenamate injections in treatment of acute painful conditions in rheumatic diseases. Ceska Revmatologie 1994:79-81.
80. Beltrán Gutiérrez J, Fernández del Vallado P, Gijón Baños J. Double-blind study using flufenamic acid (F.I. 440) and oxyphenylbutazone in rheumatoid arthritis and ankylosing spine. Revista Española de Reumatismo y Enfermedades Osteo-Articulares 1968;12:219-21.
81. Bernstein RM, Calin HJ, Ollier S, Calin A. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylitis. European Journal of Rheumatology and Inflammation 1992;12:6-13.
82. Bird HA, Le Gallez P, Astbury C, Looi D, Wright V. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica 1986;4(7):457-62.
83. Bocci U, Bignotti N, Luzi T, Pigani G, De Santis AM. Controlled clinical study of the therapeutic activity and side-effects of a preparation of indomethacin in lactocomplex [Italian]. Reumatismo 1972;24(1):1-9.
84. Burdeinyi AP. Double-blind trial of the therapeutic efficacy of voltaren and indomethacin in Bechterew's disease. Terapevticheskii Arkhiv 1981;53(7):107-11.
85. Dougados M, Calin A, Zeidler H. Double-blind, placebo-controlled clinical study over 52 weeks on M. Bechterew patients with 20 μg Piroxicam, 15 μg and 22, 5 μg Meloxicam. Zeitschrift für Rheumatologie 2000;59(Suppl 3):49.
86. Droste U. Tolmetin 400 μg capsules in treatment of ankylosing spondylitis [Tolectin (Tolmetin) 400 Mg Kapseln in Der Behandlung Der Spondylitis Ankylosans]. Therapiewoche 1979;29:8901-2.
87. Droste U. Pirprofen in the treatment of ankylosing spondylitis. A 3-week open trial [German]. Fortschritte der Medizin 1985;103:173-5.
88. Dutu A, Bolosiu HD, Parasca I. Treatment with tolmetin in ankylosing spondylitis. Comparative cross-study with phenylbutazone. Clujul Medical 1982;55:115-8.
89. Franke M, Manz G. Bumadizone-calcium-semihydrate (Eumotol) and oxyphenbutazone in the treatment of ankylosing spondylitis. A clinical double-blind study [German]. Die Medizinische Welt 1975;26(27-8):1335-40.
90. Jajic I, Nekora A, Chadri HA. Pirprofen, indomethacin and placebo in ankylosing spondylitis. Double-blind comparison [French]. La Nouvelle Presse Médicale 1982;11(33):2491-3.
91. Leng Levy J, David Chausse J, David Chausse F. Clinical results of tanderil administration in gout and rheumatic pelvispondylitis [French]. Journal de Médecine de Bordeaux et du Sud-Ouest 1963;140:1679-86.
92. Maier-Lenz H, Ringwelski L. Results of a controlled double-blind comparison of Exrheudon and phenylbutazone [Ergebnisse Einer Kontrollierten Doppelblindstudie mit Exrheudon Versus Phenylbutazon]. Therapiewoche 1981;31:1226-34.
93. Mayrhofer H, Aglas F, Broll H, Eberl R, Ebner W, Klein G, et al. The efficacy and tolerance of NSAIDs in patients with ankylosing spondylitis. Therapiewoche Osterreich 1991;6:121-31.
94. Mertz DP. Efficacy and tolerance of proquazone in ankylosing spondylarthritis [Wirkung und Vertraglichkeit von Proquazon bei Spondylitis Ankylosans]. Therapiewoche 1981;31:3274-8.
95. Müller-Fassbender H. Tolmetin treatment for ankylosing spondylitis [Behandlung der Spondylitis Ankylosans mit Tolectin® (Tolmetin)]. Therapiewoche 1979;29:8899-900.
96. Müller-Fassbender H. Treatment of ankylosing spondylitis with tolmetin in doses of 800 or 1200 μg [Behandlung der Spondylitis Ankylosans mit Tolectin in Einer Dosierung von 800 μg Bzw, 1200 mg]. Verhandlungen der Deutschen Gesellschaft für Rheumatologie 1981;7:335-7.
97. Orozco Medina JH. Evaluation of efficacy and tolerance of oral indoprofen in patients with ankylosing spondylitis [Valoracion de la eficacia y tolerancia de indoprofen oral en pacientes con espondilitis anquilosante]. Investigación Médica Internacional 1983;10(1):66-9.
98. Pattin S. Ankylosing spondylitis: efficacy, safety and therapeutic benefit of etodolac (600 μg daily) versus piroxicam (20 μg daily) [Spondylarthrite ankylosante: efficacité, tolérance et beneficé thérapeutique comparés de l'etodolac (600 mg/j) et du piroxicam (20 mg/j)]. Rhumatologie 1990;42(7A):207-12.
99. Reiter W, Pilger A. Ankylosing spondylitis: comparison of acemetacin and piroxicam. Therapiewoche 1984;34:7209-15.
100. Renier JC, Fournier M, Loyau G, Roux H. Ankylosing spondylitis. Comparative trial of two non-steroidal anti-inflammatory agents: pirprofen and ketoprofen [French]. La Nouvelle Presse Médicale 1982;11(33):2494-6.
101. Schattenkirchner M. Long-time results of Felden (piroxicam) in ankylosing spondylitis [Langzeiterfahrungen mit Felden (Piroxicam) bei Spondylitis Ankylosans (M. Bechterew)]. Therapiewoche 1981;31:2979-81.
102. Schattenkirchner M, Kellerer G, Kruger K. Treatment of ankylosing spondylitis: Single-blind crossover comparison of acemetacin and diclofenac [Behandlung der Spondylitis Ankylosans: Einfachblinde Cross-over-Vergleichsstudie mit Acemetacin und Diclofenac]. Therapiewoche 1986;36:5276-83.
103. Simon L, Bennet P. A comparative study of pirprofene and phenylbutazone in the treatment of ankylosing spondylitis [Etude comparative du pirprofene et de la phenylbutazone dans la spondylarthrite ankylosante]. Rheumatologie 1987;39(9):283-7.
104. Stollenwerk R, von Criegern T, Gierend M, Schilling F. Comparative study of the treatment of ankylosing spondylitis with piroxicam suppositories and indomethacin suppositories in combination with indomethacin retard capsules [Therapee der Spondylitis Ankylosans. Kurzzeitanwendung von Piroxicam-Suppositorien oder Indometacin-Suppositorien und -Retardkapseln]. Fortschritte der Medizin 1985;103(20):561-5.
105. NCT01934933. Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis. http://clinicaltrials.gov/ct2/show/NCT01934933?type=Intr&cond=Spondylitis&rcv_s=06%2F01%2F2013&rank=2 (accessed 18 June 2014).
106. NCT02089529. Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs. http://clinicaltrials.gov/ct2/show/NCT02089529?type=Intr&cond=Spondylitis&rcv_s=06%2F01%2F2013&rank=9 (accessed 18 June 2014).
107. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondyloarthropathies [French]. Revue du rhumatisme et des maladies ostéo-articulaires 1990;57(2):85-9.
108. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis and Rheumatism 2001;44(8):1876-86.
109. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28(5):527-32.
110. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
111. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Current Medicinal Chemistry 2002;9(10):1033-43.
112. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-79.
113. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases 2004;63(11):1438-44.
114. Braun J, Landewé R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis and Rheumatism 2006;54(5):1646-52.
115. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369(9570):1379-90.
116. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargoas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70(6):896-904.
117. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005;352(11):1092-102.
118. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 2013;72(4):517-24.
119. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. Journal of Rheumatology 1994;21(12):2281-5.
120. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010;376(9736):173-9.
121. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
122. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis and Rheumatism 1991;34(10):1218-27.
123. Dougados M. Diagnostic features of ankylosing spondylitis. British Journal of Rheumatology 1995;34(4):301-3.
124. Dougados M, Paternotte S, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Annals of the Rheumatic Diseases 2011;70(2):249-51.
125. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases 2003;62(1):20-6.
126. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354(9196):2106-11.
127. Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology 2010;49(7):1317-25.
128. Feenstra J, Heerdink ER, Grobbee DE, Stricker BH. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine 2002;162(3):265-70.
129. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. Journal of Rheumatology Supplement 1991;28:6-10.
130. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Annals of Internal Medicine 1991;115(10):787-96.
131. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Journal of Rheumatology 1994;21(12):2286-91.
132. Gossec L, van der Heijde D, Meilian A, Krupa DA, James MK, Cavanaugh PF, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Annals of the Rheumatic Diseases 2005;64(11):1563-7.
133. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Annals of Internal Medicine 1988;109(5):359-63.
134. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Annals of Internal Medicine 2006;144(6):427-37.
135. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
136. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
137. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
138. Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Annals of the Rheumatic Diseases 2009;68(9):1466-9.
139. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. Journal of Rheumatology 1994;21(9):1694-8.
140. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332(7553):1302-8.
141. Khan MA, van der Linden SM, Kushner I, Valkenburg HA, Cats A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. Arthritis and Rheumatism 1985;28(1):40-3.
142. Khan MA, van der Linden SM. A wider spectrum of spondyloarthropathies. Seminars in Arthritis and Rheumatism 1990;20(2):107-13.
143. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2012;71(10):1623-9.
144. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343(8905):1075-8.
145. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
146. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchirst MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315(7119):1333-7.
147. Machado P, Landewé R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2010;69(8):1465-70.
148. Machado P, Landewé R, Braun J, Hermann KG, Baraliakos X, Baker D, et al. A stratified model for health outcomes in ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70(10):1758-64.
149. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-offvalues for disease activity states and improvement scores. Annals of the Rheumatic Diseases 2011;70(1):47-53.
150. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. Journal of Rheumatology 1988;15(7):1109-14.
151. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annual Review of Pharmacology and Toxicology 1993;33:435-65.
152. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care 2001;39(10):1039-47.
153. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. Journal of Rheumatology 1999;26(9):1953-8.
154. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the Rheumatic Diseases 2012;71(10):1616-22.
155. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Annals of the Rheumatic Diseases 2014;73(8):1455-61. [DOI: 10.1136/annrheumdis-2014-205178]
156. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
157. Rudwaleit M, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. The burden of disease in patients with ankylosing spondylitis (AS) and pre-radiographic axial spondyloarthritis. Arthritis and Rheumatism 2004;50:S211.
158. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis and Rheumatism 2005;52(4):1000-8.
159. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Annals of the Rheumatic Diseases 2009;68(6):770-6.
160. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the Rheumatic Diseases 2009;68(6):777-83.
161. Said-Nahal R, Miceli-Richard C, Berthelot JM, Duché A, Dernis-Labous E, Le Blévec G, et al. The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Francais d'Etude Genetique des Spondylarthropathies. Arthritis and Rheumatism 2000;43(6):1356-65.
162. Sampaio-Barros PD, Bertolo MB, Kraemer MH, Marques-Neto JF, Samara AM. Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clinical Rheumatology 2001;20(3):201-6.
163. Schünemann H, Oxman A, Higgins J, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
164. Siegle I, Klein T, Backman JT, Saal JG, Nüsing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis and Rheumatism 1998;41(1):122-9.
165. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Annals of the Rheumatic Diseases 2009;68(Suppl 2):ii1-44.
166. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55.
167. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282(20):1921-8.
168. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed? A review and metaanalysis. Journal of Clinical Gastroenterology 1993;17(3):238-43.
169. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
170. Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheumatic Diseases Clinics of North America 2012;38(3):441-76.
171. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.
172. Van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology 2012;51(8):1388-96.
173. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Willamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis and Rheumatism 2008;58(10):3063-70.
174. van der Heijde D, Landewé R, Einstein S, Ory P, Voss D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis and Rheumatism 2008;58(5):1324-31.
175. van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 2009;68(12):1811-8.
176. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Research & Therapy 2009;11(4):R127.
177. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases 2011;70(6):905-8.
178. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatism 1984;27(4):361-8.
179. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998;38:97-120.
180. Dr Christopher Cates' EBM Web Site. Visual Rx. 3. Dr Christopher Cates' EBM Web Site, 2008.
181. Wanders AJ, Landewé RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis and Rheumatism 2004;50(8):2622-32.
182. Wanders A, Heijde D, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis and Rheumatism 2005;52(6):1756-65.
183. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
184. Zhang X, Schwarz EM, Young DA, Puzas JE, Rossier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. Journal of Clinical Investigation 2002;109(11):1405-15.
185. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Annals of the Rheumatic Diseases 2006;65(4):423-32.
186. Kroon FPB, van der Burg LRA, Ramiro S, Landewé RBM, Buchbinder R, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010952]